Sacheerome H1 FY27 Revenue Rises 10.34% to ₹84.48 Crore

Sacheerome Limited reported H1 FY27 revenue from operations of ₹84.48 crore, a 10.34% year-on-year increase, while trial production at its YEIDA facility began in September 2026. The new facility is central to the company’s stated plan to increase capacity, support commercial orders and target ₹300 crore of combined-facility revenue by FY29.

What did Sacheerome report for H1 FY27?

Sacheerome reported revenue from operations of ₹84.48 crore for the half year ended September 30, 2026, compared with growth of 10.34% from the corresponding prior-year period. Total income rose 9.84% year on year to ₹85.92 crore, according to the company’s H1 FY27 investor presentation and results disclosures.

Operating profitability improved faster than income. EBITDA increased 12.27% to ₹23.69 crore from ₹21.10 crore in H1 FY26, while the EBITDA margin rose to 27.57% from 26.98%. Profit after tax increased 12.38% to ₹16.79 crore, and basic as well as diluted earnings per share stood at ₹7.50 for the half year.

Why is the YEIDA facility important to Sacheerome’s growth plan?

The YEIDA facility completed installation and commissioning, with trial production commencing in September 2026. Sacheerome has identified the transition from trial production to commercial output as an important operational step because the facility is intended to add scale to its manufacturing network.

Management had previously said the new unit would improve automation, manufacturing efficiency, product consistency, export capabilities and scalability. The company has indicated that utilisation will increase gradually as commercial orders are transferred into production. Its disclosed annual production capacity stood at 27,60,000 kilograms as of September 30, 2026.

The company’s FY29 revenue projection for the combined Saturium and YEIDA facilities is ₹300 crore. This is a management target rather than reported financial performance, and achievement will depend on commercial production ramp-up, customer demand and operating execution at the new unit.

What are Sacheerome’s near-term revenue targets?

Sacheerome had guided for FY27 revenue of ₹200 crore during its January-March 2026 results call held on June 1, 2026. The H1 FY27 revenue figure of ₹84.48 crore provides the reported first-half position against that management guidance, but it does not confirm the full-year outcome.

The company’s longer-term facility target is ₹300 crore of revenue in FY29 from the combined Saturium and YEIDA operations. The stated expansion strategy also includes setting up global research and development, evaluation and quality centres, while using client launches and innovation opportunities to widen its reach.

Sacheerome serves FMCG customers in India and selected international markets through formulation, manufacturing, application testing and quality-control operations. Its plans include building a stronger presence in Southern India by working with pan-India and regional customers and targeting newer markets in that region.

How did the financial update reach investors?

Sacheerome had informed the exchange of a board meeting scheduled for October 31, 2026, to consider and approve unaudited financial results for the half year ended September 2026. The company subsequently released its H1 FY27 investor presentation on November 2, reporting the income and profit growth figures.

An audio recording of Sacheerome’s earnings conference call held on November 4, 2026 was made available by the company. The transcript was yet to be uploaded in the disclosed update. Investors should therefore distinguish between reported half-year financial figures, company disclosures on the facility, and management’s future revenue targets.

What does the update mean for investors and operations?

The reported figures show that EBITDA and profit grew faster than total income in H1 FY27, alongside an improvement in the EBITDA margin. For investors, the combination of revenue growth and margin expansion is relevant because it indicates better operating performance during the half year, although the figures alone do not establish a full-year trend.

The operational focus now shifts to the YEIDA facility’s commercial ramp-up. Trial production has begun, but the company has not disclosed a date for reaching full utilisation. The pace at which customer orders move to the new unit will be material to the stated FY27 guidance and the FY29 combined-facility target.

Conclusion

Sacheerome’s H1 FY27 update combines 10.34% revenue growth to ₹84.48 crore with higher EBITDA and profit growth, while the start of YEIDA trial production adds a new capacity element to its expansion plans. The results also show that the company’s margins improved modestly over the corresponding previous period.

The next disclosed operational milestone is the move from trial to commercial production at YEIDA and the gradual utilisation ramp-up. Investors can also watch for the earnings-call transcript, further disclosures on order transfers and any update to the company’s FY27 revenue guidance of ₹200 crore.